Scynexis to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Sept. 01, 2026 /CourierPR/ -- SCYNEXIS, a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences, offering insights into its pipeline of innovative therapies for severe diseases.

The company will host a fireside chat at the 12th Cantor Global Healthcare Conference in New York City on September 11, 2026, starting at 9:45 a.m. Eastern Time. A live webcast of the session will be available, with a replay accessible for 90 days post-event.

Additionally, SCYNEXIS will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held in New York City from September 14 to 16, 2026. During this conference, the company will conduct one-on-one meetings with potential investors.

SCYNEXIS is focused on developing therapies for severe and difficult-to-treat diseases with significant unmet medical needs. The company's pipeline includes SCY-770, a candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), which has received Orphan Drug designation. SCYNEXIS also has a proprietary antifungal platform called "fungerps," which includes BREXAFEMME® (ibrexafungerp tablets), the first approved drug of its class, currently licensed to GSK. SCY-247, another compound in clinical development, is part of this platform.